Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis has revealed that patients with type 2 diabetes experienced significant improvements in blood sugar control and weight as well as other risk factors when administered its obesity drug Acomplia.
Subscribe to our email newsletter
In the study, type 2 diabetes patients not currently treated with anti-diabetic medications and receiving Acomplia significantly lowered their HbA1c blood sugar levels by 0.8% from a baseline value of 7.9 as compared to a reduction of 0.3% in the placebo group. Over 50% of patients in the Acomplia arm of the trial achieved HbA1c levels below 7%, the target for good glucose control as recommended by the American Diabetes Association.
Importantly, these improvements in blood glucose control were accompanied by significant reductions in body weight of 6.7 kg in patients treated with Acomplia, while those patients on placebo lost only 2.7 kg. Furthermore, those on Acomplia benefited from improved good cholesterol and cut bad fat levels in the blood.
“The management of type 2 diabetes should not only focus on controlling blood sugar levels but also improve other risk factors such as weight, good and bad cholesterol, triglycerides and blood pressure,” said Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center at Medical City.